1. Home
  2. CERT vs KLRA Comparison

CERT vs KLRA Comparison

Compare CERT & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Certara Inc.

CERT

Certara Inc.

N/A

Current Price

$9.35

Market Cap

1.4B

Sector

Technology

ML Signal

N/A

Logo Kailera Therapeutics Inc. Common Stock

KLRA

Kailera Therapeutics Inc. Common Stock

N/A

Current Price

$11.02

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CERT
KLRA
Founded
2008
2024
Country
United States
United States
Employees
1576
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.4B
IPO Year
2020
2026

Fundamental Metrics

Financial Performance
Metric
CERT
KLRA
Price
$9.35
$11.02
Analyst Decision
Buy
Strong Buy
Analyst Count
12
6
Target Price
$8.34
★ $42.40
AVG Volume (30 Days)
★ 2.0M
944.6K
Earning Date
11-05-2026
08-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 87.50
N/A
EPS
★ N/A
N/A
Revenue
★ $418,838,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.49
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 8.75
N/A
52 Week Low
$4.45
$10.83
52 Week High
$13.88
$23.82

Technical Indicators

Market Signals
Indicator
CERT
KLRA
Relative Strength Index (RSI) 67.06 30.94
Support Level $9.06 N/A
Resistance Level $10.04 $19.15
Average True Range (ATR) 0.39 0.81
MACD 0.09 -0.06
Stochastic Oscillator 96.76 11.85

Price Performance

Historical Comparison
CERT
KLRA

About CERT Certara Inc.

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.

About KLRA Kailera Therapeutics Inc. Common Stock

Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.

Share on Social Networks: